Bonraybio CoTPE:6955 65 ROA % is 17.27% as of Dec. 2025, which is 274% above its 10-year median of 4.62. GuruFocus rates TPE:6955 with a GF Score™ of 65/100 and a GF Value™ of NT$184.74 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 856 Medical Devices & Instruments companies, Bonraybio Co ranks better than 94.63% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Bonraybio Co's annualizedNet Income for the quarter that ended in Dec. 2025 was NT$119.3 Mil.
Bonraybio Co's average Total Assets over the quarter that ended in Dec. 2025 was NT$690.8 Mil. Therefore, Bonraybio Co's annualized ROA % for the quarter that ended in Dec. 2025 was 17.27%.
The historical rank and industry rank for Bonraybio Co's ROA % or its related term are showing as below:
TPE:6955'
s ROA % Range Over the Past 10 Years
Min: -30.88 Med: 4.62 Max: 15.63
Current: 15.63
During the past 6 years, Bonraybio Co's highest ROA % was 15.63%. The lowest was -30.88%. And the median was 4.62%.
TPE:6955's ROA % is ranked better than 94.63% of 856
companies
in the Medical Devices & Instruments industry
Industry Median: 0.545
vs TPE:6955: 15.63
Bonraybio Co (TPE:6955) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Bonraybio Co ROA % Related Terms
Bonraybio Co ROA % Historical Data
* Premium members only.
The historical data trend for Bonraybio Co's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Bonraybio Co's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bonraybio Co ROA % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bonraybio Co's ROA % distribution charts can be found below:
* The bar in red indicates where Bonraybio Co's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Bonraybio Co (TPE:6955) has a ROA % of 17.27% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Bonraybio Co and its competitors. This is 274% above median its historical median of 4.62. According to the industry distribution chart, Bonraybio Co ranks #46 out of 856 companies in the Medical Devices & Instruments industry, placing it in the top 5.4%.
Is Bonraybio Co's ROA % too high?
Bonraybio Co's current ROA % of 17.27% is 274% above median its 10-year median of 4.62. The Medical Devices & Instruments industry median ROA % is 0.55. Bonraybio Co's value of 17.27% is 3068.8% above this industry median. Based on the distribution chart, Bonraybio Co ranks #46 out of 856 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bonraybio Co has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bonraybio Co's ROA % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Bonraybio Co ranks #46 out of 856 companies for ROA %. This places Bonraybio Co in the top 5% of its industry — outperforming the majority of peers. The industry median ROA % is 0.55. Bonraybio Co's value of 17.27% is 3068.8% above this benchmark. While the company's 10-year median is 4.62 vs. the industry median of 0.55, Bonraybio Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.55, based on 856 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bonraybio Co's current ROA % of 17.27% is 3068.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Bonraybio Co and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bonraybio Co's current ROA % is 17.27%, which is 274% above median its own 10-year median of 4.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bonraybio Co stock overvalued right now?
Based on GuruFocus' analysis, Bonraybio Co (TPE:6955) is currently considered Possible Value Trap. The stock's GF Value™ is NT$184.74, compared to a current price of NT$120.50 — trading 34.8% below its estimated fair value. The current ROA % is 17.27%, which is 274% above median its 10-year median of 4.62 and 3068.8% above the Medical Devices & Instruments industry median of 0.55. Bonraybio Co's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Bonraybio Co (TPE:6955), the current ROA % is 17.27% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bonraybio Co (TPE:6955) Overvalued in 2026?
Based on GuruFocus' analysis, Bonraybio Co stock appears to be undervalued.
The current stock price of NT$120.50 is trading 34.8% below its estimated GF Value™ of NT$184.74.
GuruFocus considers Bonraybio Co to be Possible Value Trap.
Key valuation signals for TPE:6955:
ROA %: 17.27% (274% above median its 10-year median of 4.62)
GF Value™: NT$184.74 vs. price of NT$120.50 (34.8% below fair value)
Industry Position: 3068.8% above the Medical Devices & Instruments median (#46 of 856)
No single metric tells the full story. See the TPE:6955 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bonraybio Co Ltd engages in research, development, and manufacturing of vitro diagnostic devices. The firm produces semen quality analyzers and Semen Analysis Systems for the clinic.
65GF Score
Get the complete analysis for TPE:6955
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6955 has been successfully added to your 
